355 related articles for article (PubMed ID: 25212503)
1. Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder.
Gotoh M; Kobayashi T; Sogabe K
Neurourol Urodyn; 2015 Nov; 34(8):730-5. PubMed ID: 25212503
[TBL] [Abstract][Full Text] [Related]
2. Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).
Gotoh M; Kobayashi T; Sogabe K
Int J Urol; 2014 May; 21(5):505-11. PubMed ID: 24304092
[TBL] [Abstract][Full Text] [Related]
3. Symptom severity and patient perceptions in overactive bladder: how are they related?
Homma Y; Gotoh M
BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
[TBL] [Abstract][Full Text] [Related]
4. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
5. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
6. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.
Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C
BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240
[TBL] [Abstract][Full Text] [Related]
7. Overactive bladder symptom severity, bother, help-seeking behavior, and quality of life in patients with type 2 diabetes: a path analysis.
Xu D; Zhao M; Huang L; Wang K
Health Qual Life Outcomes; 2018 Jan; 16(1):1. PubMed ID: 29291738
[TBL] [Abstract][Full Text] [Related]
8. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
9. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
10. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
12. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
13. Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia.
Tsujimura A; Takao T; Miyagawa Y; Okuda H; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Kiuchi H; Hirai T; Tsujimoto Y; Miura H; Kanno N; Higashino M; Nakamura Y; Nishimura K; Nonomura N
Urology; 2011 Nov; 78(5):1058-62. PubMed ID: 21908025
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study.
Vaughan CP; Johnson TM; Ala-Lipasti MA; Cartwright R; Tammela TL; Taari K; Auvinen A; Tikkinen KA
Eur Urol; 2011 Apr; 59(4):629-36. PubMed ID: 21306820
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
16. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
17. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score.
Homma Y; Yoshida M; Seki N; Yokoyama O; Kakizaki H; Gotoh M; Yamanishi T; Yamaguchi O; Takeda M; Nishizawa O
Urology; 2006 Aug; 68(2):318-23. PubMed ID: 16904444
[TBL] [Abstract][Full Text] [Related]
18. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
19. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS.
Milsom I; Kaplan SA; Coyne KS; Sexton CC; Kopp ZS
Urology; 2012 Jul; 80(1):90-6. PubMed ID: 22748867
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
